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2ABSTRACT
More than 80 mutations in the skeletal muscle ryanodine receptor gene have been found
to be associated with autosomal dominant forms of malignant hyperthermia and central core
disease and recessive forms of multi-minicore disease. Studies on the functional effect of
pathogenic dominant mutations have shown that they mostly affect intracellular calcium
homeostasis, either by rendering the channel hypersensitive to activation (malignant
hyperthermia) or by altering the amount of calcium released subsequent to physiological or
pharmacological activation (central core disease). In this report we present for the first time
data on the functional effect of 2 recently identified recessive ryanodine receptor 1 amino acid
substitutions, P3527S and V4849I as well as that of R999H, another substitution identified in
two siblings affected by multi-minicore disease. We studied the intracellular calcium
homeostasis of EBV-transformed lymphoblastoid cells from the affected patients, their healthy
relatives and control individuals. Our results show that the P3527S substitution at the
homozygous state affects the amount of calcium released after pharmacological activation with
4-chloro-m-cresol and caffeine but did not affect the size of the thapsigargin sensitive Ca2+
stores. The other substitutions had no effect on either the size of the intracellular calcium
stores, or on the amount of calcium released after ryanodine receptor activation, however both
the P3527S and V4849I had a small but significant effect on the resting [Ca2+].
3INTRODUCTION
In skeletal muscle, calcium is a key second messenger of the excitation-contraction
mechanism and the sarcoplasmic reticulum (SR) is the intracellular organelle involved in its
regulation. The SR is endowed with numerous proteins involved in calcium handling, such as
calsequestrin, a low affinity Ca2+ binding protein which functions as an intracellular Ca2+ pool,
the ryanodine receptor (RYR) which functions as the Ca2+ release channel and the ER/SR Ca2+
pump (SERCA), involved in pumping the released Ca2+ back into the lumen of the SR [1-3].
RYRs play a key role in Ca2+ homeostasis since they function as calcium release channels
through which luminal calcium is released thereby contributing actively to the elevation of the
myoplasmic [Ca2+], which is necessary for muscle contraction [4-6]. In view of its important
role as a second messenger, the intracellular [Ca2+] is finely regulated and any alteration in the
proteins involved in Ca2+ handling can potentially lead to pathological conditions. Examples of
diseases linked to a dysregulation of Ca2+ homeostasis include Malignant Hyperthermia (MH,
OMIM 145600), Central Core Disease (CCD, OMIM 117000), Multi-minicore Disease (MmD
OMIM 602771) and Brody’s disease (OMIM 601003)[7-9]. The precise mechanism by which
genetic alterations of these proteins trigger different pathophysiological patterns remains to be
elucidated.
MmD is an autosomal recessive congenital myopathy characterized histologically by
the presence of multiple cores, which are areas devoid of mitochondria, thus lacking oxidative
enzymes and with highly disorganized sarcomeric structures. Multiple small cores can occur in
both type 1 and type 2 fibres [10,11] and do not run the entire length of the muscle fibre. In
contrast, the histological pattern observed in biopsies from CCD patients is characterised by
fibre type uniformity, with strong predominance of type 1 fibres, core lesions with clearly
defined borders, occurring exclusively in type 1 fibres and running the entire length of the
muscle fibre [12-14]. Both MmD and CCD are characterized by hypotonia during infancy,
muscle weakness, delayed motor development; however, they differ in their pattern of muscle
weakness and modes of inheritance. Clinical and histopathological overlap between CCD and
MmD can occur [15,16], and were recently reported in two families where patients carried
recessive homozygous RYR1 mutations [17,18].
The ryanodine receptor type 1 gene (RYR1), composed of 106 exons, maps to
chromosome 19q13.1 and encodes for a protein of 5038 amino acids [19,20]. More than 80
4mutations in RYR1 have been genetically linked to MH and CCD [21,22]. Disease-causing
mutations appear to cluster in 3 defined regions of the RYR1: the cytoplasmic N-terminal
domain 1 (Cys35-Arg614; region 1), the cytoplasmic central domain (Asp2129-Arg2458;
region 2) and the C-terminal hydrophobic domain (Ile3916-Ala4942; region 3). In Malignant
hyperthermia, a pharmacological disorder triggered by exposure to volatile anaesthetics and/or
muscle relaxants in genetically predisposed individuals [23-25], disease-linked mutations
predominantly cluster in regions 1 and 2, whereas in CCD most RYR1 substitutions occur in
the hydrophobic pore forming region 3. MmD is genetically heterogeneous; more than 50% of
the cases presenting with the “classical” MmD phenotype harbour causative mutations in the
selenoprotein N gene (SEPN1) [26]; however, a significant proportion of the remaining cases
carry recessive RYR1 mutations, distributed over all the gene.
Previous studies have demonstrated that EBV-immortalized human B-lymphocytes
express the skeletal muscle isoform of the RYR [27,28] and that they could be used as a model
to test the effect of mutations on RYR function. In order to shed light on the functional impact
of RYR1 mutations linked to MmD, in the present report we investigated the influence of
naturally occurring RYR1 mutations identified in patients with MmD and/or CCD, on
intracellular Ca2+ homeostasis and pharmacological RYR activation, of EBV-immortalized B-
lymphocytes. The clinical genotypes and phenotypes of the two MmD cases have been
described previously [17, 18] and are linked to the RYR1 mutations P3527S and V4849I. We
also included in this study the functional effect of the R999H RYR1 substitution, which was
identified at the heterozygous state, in a family in which two siblings were affected by
MmD/CCD.
5EXPERIMENTAL PROCEDURES
MATERIALS
Thapsigargin and fura-2/AM were from Calbiochem. Caffeine was from Merck (Darmstadt,
Germany), 4-chloro-m-cresol was from Fluka Chemicals (Buchs, Swizerland). ULTRASPEC
RNA isolation system was from Biotecx laboratories (Houston, TX, U.S.A.). cDNA synthesis
kit and Taq polymerase were from Roche Molecular Biochemicals. Tissue culture media and
reagents were from Invitrogen. All other chemicals were reagent or the highest available grade.
METHODS
Patients
As SEPN1-mutations have been identified in 50% of classical severe MmD, haplotyping
studies were first performed for every family and SEPN1 was clearly excluded as a candidate
gene (data not shown).
Family 1: the P3527S substitution resulting from a C>T transition at position 10579 in exon 71
of the RYR1, was identified in 3 siblings from an Algerian consanguineous family [17]. In the
present study, we immortalized lymphoblastoid cells from 2 of the affected daughters carrying
the homozygous mutation and their healthy mother, heterozygous for this mutation. This
mutation therefore, behaved as a recessive trait. In early childhood, minicores were observed in
the biopsies of the siblings but when the probands were biopsied again during adult life, their
muscle showed a typical CCD pattern. Patients were classified as recessive CCD with transient
morphological presentation as MmD.
Family 2: the V4849I substitution resulting from a G>A transition at position 14545 in exon
101 of the RYR1, was identified in the homozygous state in the affected daughter and in the
heterozygous state in her healthy parents [18]. A muscle biopsy in the proband revealed
marked type 1 predominance with presence of few minicores and central cores. A muscle MRI
showed the typical skeletal muscle involvement that has been associated in patients with CCD.
A diagnosis of CCD secondary to a recessive RYR1 mutation was made.
Family 3: the R999H substitution resulting from a G>A transition at position 2996 in exon 24
of the RYR1 gene, was identified in the heterozygous state in a patient classified as MmD, with
short cores present only in type 1 fibres. Her brother was mildly affected, also carried the
mutation in the heterozygous state and presented short cores in both fibre types. The mother
6had a normal CT scan, no signs of any neuromuscular disorder, but was later found to also
harbour the R999H substitution at the heterozygous state.
Lymphoblastoid cell lines
Heparinized peripheral blood was obtained from healthy control individuals, family members
of patients and patients with core myopathy carrying proven RYR1 mutations. Mononuclear
cells were isolated and transformed with Epstein Barr Virus according to the protocol of
Neitzel [29]. Cells were cultured in RPMI medium supplemented with 10% foetal bovine
serum, 2 mM glutamine, 1 mM sodium pyruvate and 100 Units of penicillin and streptomycin.
Mutation screening
Total RNA was isolated using an RNA isolation kit. RNA was converted into cDNA using a
commercially available kit following the manufacturers instructions. Approximately 100 ng of
cDNA were used for each PCR amplification using a 2720 Thermal cycler (Applied
Biosystem). The following primes were used to amplify cDNA: 24F 5’-
TGGACCGTCTGGCAGAAAATG-3’, 24R 5’GGTCAGGAGGCTCGATGTTGTA-3’; 71F
5’-TCCGGTGGCTCGGACCAGGAA-3’, 71R 5’-TTGGCCAGCGTGATGAGGTCTT-3’;
101F 5’-ACCTGGCCCCATCCTG-3’, 101R 5’-GCTAGGGGAGGGGCTCAC-3’.
Amplification conditions were: 5 min 95 °C followed by 40 cycles: 30 s annealing at 56 °C
(24F/R), 71 °C (71F/R) and 60 °C (101 F/R), 60 s extension at 72 °C and 30 sec denaturation
at 94 °C, followed by a final extension for 3 min at 72 °C. The presence of the nucleotide
substitutions was detected by restriction enzyme digestion using Bst UI, Hha I or Acc I. In
order to demonstrate that the cDNA preparations used for PCR amplification were not
contaminated by genomic DNA, a PCR reaction spanning exons 39-40 was carried out as
previously described [28].
Intracellular calcium measurements
Changes in the intracellular Ca2+ concentration, [Ca2+]i, of the lymphoblastoid cells were
monitored with the fluorescent Ca2+ indicator fura-2. Experiments were carried out on
populations of cells, in an LS-50 Perkin Elmer spectrofluorimeter as previously described
[28,30,31] or at the single cell level by digital imaging microscopy as previously described
[32]. In the latter case, lymphoblastoid cells loaded with 5µM fura-2 were allowed to attach to
poly-L-lysine treated glass coverslips for 10 minutes prior to the experiments. Individual cells
were stimulated with a 12-way 100 mm diameter quartz micromanifold computer controlled
7microperfuser (ALA Scientific) as described [32]. On-line (340 nm, 380 nm and ratio)
measurements were recorded using a fluorescent Axiovert S100 TV inverted microscope (Carl
Zeiss GmbH, Jena, Germany) equipped with a 40x oil-immersion Plan-NEOFLUAR objective
(0.17 NA), filters (BP 340/380, FT 425, BP 500/530). The cells were analyzed using an
Openlab imaging system and the average pixel value for each cell was measured at excitation
wavelengths of 340 and 380 nm.
Statistical analysis
Statistical analysis was performed using the Student’s t test for paired samples or using
ANOVA when more than two groups were compared. Origin computer program (Microcal
Software, Inc., Northampton, MA, USA) was used for statistical analysis and dose response
curve generation. The EC50 and Rmax values were calculated using the Origin program from
sigmoidal curve fitting of all the data points.
8RESULTS
RYR1-mutation analysis
The EBV-immortalised lymphoblastoid cells were analysed by RT-PCR to verify the
presence of the different mutations at the transcriptional level. Figure 1 shows the results after
digestion of the PCR amplified cDNA obtained from the lymphoblastoid cell lines from
controls or 3 probands, each carrying one of the identified mutations. The primers used to
amplify the cDNA fragment depicted in figure 1A span exons 39-40 and the size of the
amplified band (338 bp) corresponds to that of the cDNA, since the corresponding genomic
sequence would encompass intron 39 and yield a fragment of 1400 bp. The G2996>A
substitution in exon 24 abolishes a Bst UI restriction site, resulting in the presence of four
bands of 127, 93, 47 and 46 bp at the heterozygous state and of three bands of 127, 47 and 46
bp in controls (figure 1B, lanes 1-4). The C10579>T substitution in exon 71 abolishes a Hha I
restriction site, resulting in the presence of two bands of 118 and 38 bp after digestion of the
amplified cDNA from the homozygous proband with Hha I and of three bands of 86, 38 and 32
bp after digestion of the amplified cDNA from controls (fig.1 B, lanes 5-8). The G14545>A
substitution in exon 101 abolishes an Acc I restriction site. After digestion, the amplified
cDNA from the homozygous carrier remains uncut (176 bp fragment), whereas digestion of the
amplified cDNA from controls yields two bands of 118 and 58 bp (figure 1B, lanes 9-12).
Resting [Ca2+]i and status of the intracellular Ca
2+ stores in lymphoblastoid cells carrying
RYR1 substitutions
The aim of this work was to establish the characteristics of the intracellular Ca2+ pools
of lymphoblastoid cells carrying the RYR1 substitutions R999H, P3527S and V4849I. To this
end, we first analysed the resting [Ca2+]i of lymphoblastoid cells from mutation carriers and
compared it to that observed in cells from control individuals (fig. 2). The resting fluorescence
intensity observed in cells from patients harbouring the R999H substitution was not
significantly different from that observed in control cells, while the presence of the other
substitutions caused a small but significant increase in fluorescence intensity ratio (P<0.04;
ANOVA). In terms of [Ca2+], the observed increases are of the order of 10-30 nM.
We next examined the status of the intracellular Ca2+ pools by comparing the peak
[Ca2+] obtained after addition of the SERCA inhibitor thapsigargin, in the absence of external
9calcium (fig. 3A). This treatment causes the release of the Ca2+ present in the intracellular pool
into the cytoplasm; since Ca2+ cannot be pumped back into the ER and no Ca2+ is present in the
extracellular medium, the peak fluorescence obtained reflects the size of the rapidly releasable
intracellular Ca2+ stores [27,30,31]. When cells from controls or mutation-bearing individuals
were treated with 400 nM thapsigargin, no significant differences were observed in the amount
of Ca2+ released, suggesting that none of the mutations affect the size of the thapsigargin-
sensitive intracellular stores (fig. 3 B).
Sensitivity of lymphoblastoid cell lines to pharmacological activation with RYR agonists
In the next set of experiments, we tested the sensitivities of lymphoblastoid cells to the
RYR1 agonists 4-chloro-m-cresol (4-cmc) and caffeine. We first performed dose-response
curves to 4-cmc by studying changes in [Ca2+]i, in cell populations, in Ca
2+-free Krebs Ringer
and expressed these as % release with respect to the thapsigargin-sensitive pool (set as 100 %).
4-cmc is a specific activator of the ryanodine receptor and can be used pharmacologically to
discriminate between MHN and MHS [33-35]; when RYR1-mutations are associated with the
MHS phenotype, the sensitivity of the receptor to 4-cmc is increased [28,34]. Figure 4 shows
the dose response curves to 4-cmc in lymphoblastoid cells from control individuals, from
individuals harbouring the R999H substitution and from individuals harbouring the P3527S
and V4849I substitutions at the homozygous and heterozygous states. None of the substitutions
caused a significant shift in the dose response curve to lower agonist concentration, while the
P3527S substitution at the homozygous state, caused a small but significant reduction in the
amount of Ca2+ released by 4-cmc (the % maximal releases were 77.6±3.0 and 89.3±3.3 for
homozygous P3527S and controls, respectively. Students’t test P<0.02).
In order to gain more information on how different RYR1 mutations may affect the
response to different pharmacological activators and since under our experimental conditions
in cell populations we were unable to detect caffeine-induced changes in [Ca2+]i, we next
examined the Ca2+ response of lymphoblastoid cells at the single cell level. Individual cells
were stimulated by a pressure pulse of either 4-cmc or caffeine and the release of Ca2+ was
assessed by calcium imaging. This technique is more sensitive and allowed us to detect
changes in the [Ca2+]i even after addition of caffeine (fig. 5); it also helped us monitor the
proportion of cells responding to a particular concentration of agonist. Figures 6 and 7 show
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the 4-cmc and caffeine dose-response curves obtained from control cells and from cells from
mutation-bearing individuals. These curves were generated taking into consideration only cells
responding to the added agonist: using these values, only the P3527S homozygous mutation
caused a reduction in the amount of Ca2+ released by 4-cmc while none of the substitutions
caused a significantly change the maximal amount of Ca2+ released by caffeine (figure 6 and 7,
compare curve in panel A with those in panels B-F). The sensitivities to 4-cmc and caffeine
and maximal change in [Ca2+]i induced in lymphoblastoid cells bearing the different
substitutions are shown it Table I. The maximal fluorescence change (Rmax) and EC50 were
calculated from the data shown in figures 6 and 7 and the given values were calculated using
the Origin program for sigmoidal curve generation. The results show: (i) that none of the
substitutions significantly reduced the sensitivity of the RYR1 to activation to both caffeine
and 4-cmc, while in some cases there was a shift to higher agonist concentrations; (ii) the
Rmax value for 4-cmc induced Ca2+ release was only different for the P3527S homozygous
carriers and (iii) the Rmax values obtained for caffeine and 4-cmc were of comparable
magnitude. Table II compares the % responding cells at each concentration of 4-cmc and
caffeine in lymphoblastoid cells carrying different substitutions. It is apparent (i) that the %
cells responding to 4-cmc was always higher than that responding to caffeine; (ii) that the
number of cells harbouring the homozygous substitution P3527S responding to any
concentration of caffeine was always lower than that from controls or from carriers of the two
other substitutions. If the cumulative change in fluorescence of all analysed cells was taken
into account (i.e. responding and non-responding cells), only the P3527S cells bearing the
homozygous substitutions showed a significantly lower peak fluorescence change in response
to 4-cmc and caffeine (mean values±s.e.m. were 0.11±0.03 and 0.05±0.02 for P3527S
homozygous carriers vs 0.23±0.04 and 0.12±0.03 for controls, respectively. P<0.05 Student’s t
test).
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DISCUSSION
During the past decade a number of reports dealing with mutations in the skeletal
muscle RYR1 Ca2+ channel, their genetic association to neuromuscular disorders and impact on
protein function have appeared [36-39]. While it is well established that most MH-causing
mutations affect the RYR1 by making it hypersensitive to activating substances, and CCD-
causing mutations affect the amount of Ca2 released after activation, not much is known about
the functional effect of RYR1 mutations leading to MmD. In the present report, we investigated
the functional effect of three amino acid substitutions linked to a mixed MmD/CCD phenotype
[17,18] by studying the Ca2+ homeostasis of lymphoblastoid cells established from the patients.
Two of these were clearly inherited as recessive mutations. Under our experimental conditions,
only the P3527S substitution at the homozygous state significantly affected intracellular Ca2+
homeostasis. Our results show that unlike many CCD-linked mutations, the presence of this
mutation did not affect the size of the intracellular Ca2+-pools, but rather affected the total
amount of Ca2+ released by pharmacological activation of the RYR. This finding implies that
(i) the presence of the P3527S substitution on one allele alone is not sufficient to significantly
alter the functional properties of the RYR; (ii) the homozygous substitution does not diminish
the size of the Ca2+ stores and therefore does not cause the channel to become leaky; (iii) its
presence causes a decrease in the maximal amount of Ca2+ released by 4-chloro-m-cresol and
caffeine. In view of the fact that the substituted residue lies in the vicinity of binding sites for
calmodulin and S100 [40,41], two proteins which enhance channel opening and promote Ca2+
release [42,43], and based on the fact that proline, an amino acid known to disrupt α-helices, is
substituted by a residue having a polar uncharged side chain, one may hypothesise that the
P3527S substitution interferes with the binding of accessory proteins involved in stabilizing the
RYR in the open state in the native tetrameric (in cells heterozygous for the mutation)
conformation and that the presence of wild type channels within the tetramer are sufficient to
bind regulatory proteins and therefore allow “normal“ Ca2+ release after activation.
Alternatively, the decrease of calcium released after the addition of 4-chloro-m-cresol, may
reflect the fact that the mutation lies in proximity of the binding site for this agonist [44].
As to the other two substitutions, under our experimental conditions we found that
channels carrying the R999H substitution behave like their wild type counterpart both in terms
of resting [Ca2+], and total amount of Ca2+ released after RYR1 activation. We would like to
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point out that genetic investigation into the family carrying the R999H substitution revealed
that also the unaffected mother (with normal clinical examination and muscle CT scan) was a
carrier of this substitution. Since the entire RYR1 of the proband was sequenced and found to
contain no other amino acid substitutions, it is unlikely that this substitution alone is
pathological at the heterozygous state and substitutions in other genes must be responsible for
the MmD/CCD phenotype. As far as the V4849I mutation is concerned, lymphoblastoid cells
carrying this substitution at the homozygous and heterozygous states behaved like wild type
cells in terms of Ca2+ store content and total amount of Ca2+ released after pharmacological
RYR activation; however they exhibited a small but significant increase in their resting [Ca2+].
Sambuughin et al. [45] recently reported that the V4849I substitution may be causative of MH
since it was found in one proband with a very strong IVCT. On the other hand, Monnier et al.
reported that this same substitution was also found in a control individual [46]. Our data show
that cells carrying the V4849I substitution do not show an increased sensitivity to either 4-
chloro-m-cresol, or caffeine, thus it is unlikely to be causative of MH when present (alone)
either at the heterozygous and homozygous states. We are aware that lymphoblastoid cells do
not express all the proteins which interact with the RYR1 in the sarcoplasmic reticulum, and
we do not think that the conserved V4849I residue is involved in protein-protein interaction
since it is predicted to be within a hydrophobic transmembrane domain (TM8) [19,47].
However, since the presence of this substitution affects the resting [Ca2+] it may influence
channel function in a way that could not be detected by our system.
An interesting observation emerging from the present report concerns the response of
the lymphoblastoid cells to caffeine. We had previously attempted to obtain changes in [Ca2+]
in response to caffeine in populations of lymphoblastoid cells however, the results were not
reproducible. In light of the results obtained on single cell measurements, we suggest that only
a proportion of lymphoblastoid cells respond to caffeine; since spectrofluorimetric
measurements average changes in [Ca2+] occurring in millions of cells, if fewer than 50% of
the cells respond synchronously, no increase in fluorescence can be observed. Imaging analysis
revealed that the number of cells responding to different concentrations of caffeine was <50%,
while that responding to 4-chloro-m-cresol was always higher, even though the cells were
viable and fluorescent. Furthermore, both agonists induced comparable global increases in
[Ca2+] in responding cells. We do not know the reason for this but it may reflect the quenching
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effect of caffeine on fura-2 fluorescence as well as the fact that the lymphoblastoid cell lines
are of a polyclonal nature. The results obtained averaging all cells stimulated with 4-chloro-m-
cresol and caffeine are consistent, and demonstrate that only the P3527S mutation causes
significant alterations in Ca2+ homeostasis. The decrease in maximal amount of Ca2+ released
after pharmacological activation was observed in cell lines established from two individuals
carrying the same homozygous substitution and in none of the other cell lines thus we think
that it is unlikely to reflect the selection of particular clones of cells.
One of the questions remaining to be answered is how RYR1 mutations differently
modify intracellular Ca2+ dynamics and contribute to the pathophysiology of MH, CCD and
MmD. In MH-susceptible individuals, most mutations shift the sensitivity of the receptor to
lower agonist concentration and the clinical signs translate to a hypermetabolic state triggered
by a hyperactive RYR. In CCD, the function of the RYR calcium channel is altered either
because mutations cause the channels to become excessively leaky or because they become
unable to transport Ca2+ efficiently [36,37, 39]. The present results suggest that at least as far as
the MmD-linked P3527S recessive mutation is concerned, the RYR channels do not become
leakier but rather transport less Ca2+ upon activation. Single channel recording experiments
will be important in order to confirm whether this mutation renders the channel unstable in the
open state.
In conclusion, the present data strongly support a causative role for the P3527S RYR1
mutation at the homozygous level for the CCD/MmD phenotype; on the other hand our results
show that the functional properties of RYR1 carrying the R999H substitution are not different
from controls and are most likely not causative of CCD/MmD. As to the V4849I substitution,
our results show that its presence does not cause a shift in the sensitivity to pharmacologic
activation of the ryanodine receptor, or cause alterations in the amount of thapsigargin, 4-
chloro-m-cresol and caffeine-induced calcium release. However, since its presence affected the
resting calcium concentration, the V4849I substitution may perturb the function of the
ryanodine receptor channel in a way which was not discernable in the present study. Finally,
these results confirm that lymphoblastoid cells can be used as a tool to study the effects of
causative mutations vs polymorphisms among RYR1 substitutions, however one must keep in
mind that these cells do not express all the proteins of the skeletal muscle sarcoplasmic
reticulum involved in calcium homeostasis.
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Table I: Rmax and EC50 for 4-chloro-m-cresol and caffeine activation of calcium release from
control and RYR1 carrying the indicated amino acid substitutions.
Cell type Rmax4cmc
EC50
4cmc (µM)
Rmax
caffeine
EC50
Caffeine
(mM)
WT  0.36± 0.03 136± 33 0.33±0.03 1.08±0.33
Heterozygous R999H 0.37±0.14 191±27 0.34±0.02 1.40±0.27
Homozygous P3527S 0.23±0.04* 75±18 0.43±0.04 1.21±0.18
Heterozygous P3527S 0.34±0.04 157±21 0.40±0.03 1.56±0.47
Homozygous V4849I 0.36±0.05 184±23 0.36±0.03 1.39±0.31
Heterozygous V4849I 0.47±0.05 204±36 0.43±0.03 1.94±0.29
Values represent the mean±s.e.m. (the number of cells analysed is given in the legend to
figures 6 and 7).
* P<0.009 Student’s t test.
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Table II: Number of lymphoblastoid cells carrying RYR1 substitutions, responding to
different concentrations of caffeine and 4-chloro-m-cresol.
Responding cells  (% of total)
[Caffeine] (mM) 0.5 mM 2.5 mM 5 mM 10 mM 20mM
Control 21.6% 21.3% 25% 29.2% 22.9%
R999H hetero 18.1% 21.7% 25% 14.3% 17%
P3527S homo 11.6% 14.9% 10.6% 10% 17.6%
P3527S hetero 20.1% 33% 22.4% 20% 18.4%
V4849I homo 26.3% 43.8% 40% 18.3% 17.8%
V4849I hetero 20.2% 35.6% 14.6% 18.9% 19.2%
Responding cells  (% of total)
[4cmc] (µM) 75µM 150µM 300µM 600µM 1000µM
Control 31.6% 40% 39.3% 61.3% 29.7%
R999H hetero 20.7% 26.7% 47.4% 30.3% 32%
P3527S homo 41.7% 42.9% 38.5% 50% 39.3%
P3527S hetero 29.4% 29.1% 53.8% 50% 22.5%
V4849I homo 35.7% 40% 35% 26.1% 34.8%
V4849I hetero 38.9% 47.6% 60% 57.9% 60%
The number of cells analysed ranged between 15-302.
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FIGURE LEGENDS
Figure 1: EBV-immortalised B-cells from patients express a mutated ryanodine receptor.
Polyacrylamide gels showing PCR-amplification of cDNA using the primer pairs indicated in
the Methods section. Panel A- amplification of cDNA spanning RYR1 exons 38 and 40 from
control (lane 1), R999H (lane 2), P3527S (lane 3) and V4849I (lane 4) yields a band of 338 bp
corresponding to the expected cDNA product, and none from genomic DNA amplification.
Panel B- Lanes 1-4: amplification of exon 24 of the RYR1 gene for the R999H mutation. Lanes
1 and 3, undigested cDNA, lanes 2 and 4, cDNA after digestion with BstU I. Lanes 1, 2
control, lanes 3,4 patient harbouring the heterozygous R999H substitution. Lanes 5-8:
amplification of exon 71 of the RYR1 gene for the P3527S mutation. Lanes 5 and 7 undigested
cDNA, lanes 6 and 8, cDNA after digestion with Hha I. Lanes 5, 6 control, lanes 7, 8 patient
harbouring the homozygous P3527S substitution. Lanes 9- 12: amplification of exon 101 for
V4849I mutation. Lanes 9 and 11, undigested cDNA; lanes 10 and 12 cDNA after digestion
with Acc I. Lanes 9 and 10 control, lanes 11 and 12, patient harbouring the homozygous
V4849I substitution.
Figure 2: Resting calcium concentration of EBV-immortalised lymphoblastoid cells from
control individuals and individuals bearing different RYR1-mutations. Average resting
myoplasmic [Ca2+] of cells from controls and individuals bearing the indicated RYR1
mutations. Values are the mean (±s.e.m. of n= 43-98). Data were determined in fura-2-loaded
lymphoblastoid cells (1x106cells/ml) in nominally Ca2+-free Krebs Ringer supplemented with
0.5 mM EGTA. The [Ca2+]i was measured using the fluorescent Ca2+ indicator fura-2.
(*P<0.04).
Figure 3: Thapsigargin-sensitive [Ca2+]i  stores of EBV-immortalised lymphoblastoid cells
from control individuals and RYR1-mutated patients are not  significantly different. (A)
Representative trace of the effect of 400 nM thapsigargin on the [Ca2+]i of lymphoblastoid cells
from a control individual. Conditions as described in fig. 2. Once the steady state was obtained,
400 nM thapsigargin were added where indicated by the arrow. (B) The mean increase in
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[Ca2+]i (=peak ratio 340/380 nm-resting ratio 340/380 nm) induced by the addition of 400 nM
thapsigargin was calculated. Results are the mean ±s.e.m. of 6-23 experiments.
Figure 4:  Dose dependent 4-chloro-m-cresol induced changes in [Ca2+]i in EBV-
immortalized lymphoblastoid cells from control individuals and patients carrying
different RYR1 mutations. The increase in [Ca2+]i induced by the indicated concentrations of
4-chloro-m-cresol were calculated as a percentage of the maximal amount which could be
released by 400 nM thapsigargin (which was set at 100%).  Each point represents the mean
(±s.e.m) of the ∆ fluorescence of 4-13 measurements. Sigmoidal dose response curves were
generated using the Origin software. A: Control; B: heterozygous R999H RYR1-substitution; C
and D P3527S substitution, C: 2 homozygous daughters and D heterozygous mother; E and F
V4849I mutation, E homozygous daughter, F, heterozygous parents.
Figure 5: Calcium release stimulated by caffeine in individual EBV-immortalized
lymphoblastoid cells from a control individual. A , phase contrast; B-E, single cell
intracellular [Ca2+]i measurements of fura-2-loaded lymphoblastoid cells from control
individuals; B, resting [Ca2+]I, C, 36 sec, D, 50 sec and E, 77 sec after the application of 10mM
caffeine. Cells were individually stimulated by addition of caffeine in Krebs-Ringer medium
containing 1 mM CaCl2. The trace in the right hand panel is a representative trace obtained
after stimulation of a single cell with 5mM caffeine (arrow).
Figure 6: Changes in [Ca2+]i induced by 4-chloro-m-cresol in EBV-immortalized
lymphoblastoid cells from control individuals and from patients harbouring different
RYR1 mutations. Single cell intracellular Ca2+ measurements of fura-2 loaded cells were
measured before and after the addition of the indicated concentration of 4-chloro-m-cresol. The
curves show the 4-chloro-m-cresol dependent change in [Ca2+], expressed as ∆ in fluorescence
ratio (peak ratio 340/380 nm-resting ratio 340/380 nm). Each point represents the mean
(±s.e.m) of the ∆ fluorescence of 4-19 measurements. The curve was generated using a
sigmoidal dose response curve function included in the Origin software.
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Figure 7: Changes in [Ca2+]i induced by caffeine in EBV-immortalized lymphoblastoid
cells from control individuals and from patients harbouring different RYR1 mutations.
Single cell intracellular Ca2+ measurements of fura-2 loaded cells were measured before and
after the addition of the indicated concentration of caffeine. The curves show the caffeine
dependent change in [Ca2+], expressed as ∆ in fluorescence ratio (peak ratio 340/380 nm-
resting ratio 340/380 nm). Each point represents the mean (±s.e.m) of the ∆ fluorescence of 4-
15 measurements. The curve was generated using a sigmoidal dose response curve function
included in the Origin software.
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